These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 17875530)

  • 1. A prospective study of cyclosporine A treatment of patients with low-risk myelodysplastic syndrome: presence of CD55(-)CD59(-) blood cells predicts platelet response.
    Ishikawa T; Tohyama K; Nakao S; Yoshida Y; Teramura M; Motoji T; Takatoku M; Kurokawa M; Mitani K; Uchiyama T; Omine M
    Int J Hematol; 2007 Aug; 86(2):150-7. PubMed ID: 17875530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cyclosporine A based therapy for myelodysplastic syndrome].
    Li ZL; Gong M; Xu SH; Huang FZ; Chen YR; Ma YG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Oct; 13(5):867-70. PubMed ID: 16277860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of CD55- and CD59-deficient granulocytic populations in patients with myelodysplastic syndrome.
    Kaiafa G; Papadopoulos A; Ntaios G; Saouli Z; Savopoulos C; Tsesmeli N; Kontoninas Z; Chatzinikolaou A; Tsavdaridou V; Klonizakis I; Hatzitolios A
    Ann Hematol; 2008 Apr; 87(4):257-62. PubMed ID: 18158579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Curative effects of cyclosporin A therapy upon myelodysplastic syndrome].
    Chen SC; Jiang B; Da WM; Gong M; Guan M
    Zhonghua Yi Xue Za Zhi; 2006 Oct; 86(38):2711-5. PubMed ID: 17199984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclosporin A in myelodysplastic syndrome: a preliminary report.
    Dixit A; Chatterjee T; Mishra P; Choudhary DR; Mahapatra M; Saxena R; Choudhry VP
    Ann Hematol; 2005 Sep; 84(9):565-8. PubMed ID: 15809884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunosuppressive Therapy: Exploring an Underutilized Treatment Option for Myelodysplastic Syndrome.
    Haider M; Al Ali N; Padron E; Epling-Burnette P; Lancet J; List A; Komrokji R
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S44-8. PubMed ID: 27521323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of myelodysplastic syndrome with cyclosporin A.
    Chen S; Jiang B; Da W; Gong M; Guan M
    Int J Hematol; 2007 Jan; 85(1):11-7. PubMed ID: 17261496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclosporin A therapy for patients with myelodysplastic syndrome: multicenter pilot studies in Japan.
    Shimamoto T; Tohyama K; Okamoto T; Uchiyama T; Mori H; Tomonaga M; Asano Y; Niho Y; Teramura M; Mizoguchi H; Omine M; Ohyashiki K
    Leuk Res; 2003 Sep; 27(9):783-8. PubMed ID: 12804635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes.
    Yazji S; Giles FJ; Tsimberidou AM; Estey EH; Kantarjian HM; O'Brien SA; Kurzrock R
    Leukemia; 2003 Nov; 17(11):2101-6. PubMed ID: 12931212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hematologic response predictor factors in adults with myelodysplastic syndromes (SMD) treated with cyclosporin A (CSA)].
    Zamora-Pérez E; López-Karpovitch X
    Gac Med Mex; 2015; 151(3):345-53. PubMed ID: 26089271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclosporine-responsive thrombocytopenia in a patient with chloramphenicol-associated myelodysplastic syndrome.
    Arber C; Buser A; Heim D; Gratwohl A; Tichelli A; Passweg JR
    Eur J Haematol; 2006 Mar; 76(3):255-7. PubMed ID: 16451398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A preliminary report on treatment of myelodysplastic syndrome with cyclosporin a and androgen].
    Wang JW; Ning F; Liu XD; Lou JX; Chen P; Liu B
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2004 Dec; 12(6):855-7. PubMed ID: 15631678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes.
    Broliden PA; Dahl IM; Hast R; Johansson B; Juvonen E; Kjeldsen L; Porwit-MacDonald A; Sjoo M; Tangen JM; Uggla B; Oberg G; Hellstrom-Lindberg E
    Haematologica; 2006 May; 91(5):667-70. PubMed ID: 16670072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
    Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R
    Ann Hematol; 2006 Mar; 85(3):174-80. PubMed ID: 16408206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term improvement of hematopoiesis following cyclosporine treatment in a patient with myelodysplastic syndrome.
    Berer A; Ohler L; Simonitsch I; Thalhammer R; Lechner K; Geissler K
    Wien Klin Wochenschr; 1999 Oct; 111(19):815-8. PubMed ID: 10568013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pilot study using tacrolimus rather than cyclosporine plus antithymocyte globulin as an immunosuppressive therapy regimen option for severe aplastic anemia in adults.
    Zhu X; Guan J; Xu J; Wei J; Jiang L; Yin J; Zhao L; Zhang Y
    Blood Cells Mol Dis; 2014 Sep; 53(3):157-60. PubMed ID: 24931461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of a small population of paroxysmal nocturnal hemoglobinuria-type cells in the management of bone marrow failure.
    Nakao S; Sugimori C; Yamazaki H
    Int J Hematol; 2006 Aug; 84(2):118-22. PubMed ID: 16926132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclosporin A and thalidomide in patients with myelodysplastic syndromes: Results of a pilot study.
    Xiao Z; Xu Z; Zhang Y; Qin T; Zhang H; Fang L
    Leuk Res; 2011 Jan; 35(1):61-5. PubMed ID: 20591481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclosporine Combined with Levamisole for Lower-Risk Myelodysplastic Syndromes.
    Li X; Shi J; Wang M; Nie N; Shao Y; Ge M; Huang J; Huang Z; Zhang J; Zheng Y
    Acta Haematol; 2015; 134(3):138-45. PubMed ID: 25925993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prognostic factors of cyclosporine A combined with danazol with or without thalidomide in myelodysplastic syndrome treatment with low-percentage bone marrow blasts].
    Zhang YD; Xu ZF; Qin TJ; Li B; Qu SQ; Pan LJ; Jiao M; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2021 May; 42(5):376-382. PubMed ID: 34218579
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.